October 22, 2016 12:11 PM ET


Company Overview of Eleven Biotherapeutics, Inc.

Company Overview

Eleven Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of protein therapeutics to treat eye diseases primarily in the United States. The company develops its therapeutics through AMP-Rx, a proprietary protein engineering platform. Its lead product candidate is EBI-005, which has completed Phase III clinical trials for the treatment of patients with dry eye disease and allergic conjunctivitis. The company is also developing EBI-031 that is in preclinical development to treat diabetic macular edema; and a product candidate as an intravitreal injection for the treatment of certain retinal diseases, such as wet age-related macular degeneration. Eleven...

215 First Street

Suite 400

Cambridge, MA 02142

United States

Founded in 2008

19 Employees





Key Executives for Eleven Biotherapeutics, Inc.

Eleven Biotherapeutics, Inc. does not have any Key Executives recorded.

Eleven Biotherapeutics, Inc. Key Developments

Eleven Biotherapeutics, Inc. Presents at 2016 BIO Investor Forum, Oct-18-2016 11:30 AM

Eleven Biotherapeutics, Inc. Presents at 2016 BIO Investor Forum, Oct-18-2016 11:30 AM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, CA 94102, United States.

Eleven Biotherapeutics, Inc. Announces Executive Changes

On September 20, 2016, Eleven Biotherapeutics, Inc. entered into a Share Purchase Agreement with Viventia Bio Inc. In connection with the Acquisition, Cary G. Pfeffer, M.D. resigned from the Board of Eleven and the nominating and corporate governance committee thereof, and Messrs. Leslie L. Dan and Stephen A. Hurly were appointed to the Board of Eleven. Each of Messrs. Dan and Hurly was designated as a Class I member of the Board to serve until the 2018 annual meeting of the stockholders of the company and, in each case, thereafter until his successor has been duly elected and qualified, or until his earlier death, resignation or removal. Messrs. Dan and Hurly served as directors of Viventia prior to the Acquisition. The Board of Eleven also appointed Mr. Hurly as the company's President and Chief Executive Officer to succeed Abbie C. Celniker, with Dr. Celniker continuing to serve as a member of the Board. Also in connection with the Acquisition, Arthur P. DeCillis, M.D., Viventia's Chief Medical Officer, was appointed as Chief Medical Officer of Eleven, and Karen L. Tubridy, Eleven's Chief Development Officer, resigned from Eleven. In addition, Gregory Adams, Ph.D., Viventia's Chief Development Officer and Glen MacDonald, Ph.D., Viventia's Chief Scientific Officer, will join Eleven's management team. John J. McCabe, will continue to serve as Chief Financial Officer of Eleven.

Eleven Biotherapeutics, Inc., Viventia Bio Inc. - M&A Call

To discuss the acquisition

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

September 21, 2016
Viventia Bio Inc.
January 26, 2016
Eleven Biotherapeutics, Inc., Proprietary SuperminĀ® Albumin Variant Assets

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Eleven Biotherapeutics, Inc., please visit www.elevenbio.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.